Drug Trial Radar · NCT05682443
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
148
Actual
Start
Dec 11, 2023
Primary completion
Nov 30, 2026
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- OncoC4, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Prostate Cancer Clinical Trials Consortium
- First posted
- Jan 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled. The study is open-label, randomized with active control, multi-center study.
Conditions
- Metastatic Castration-resistant Prostate Cancer
Interventions
ONC-392 lowDrug
ONC-392 will be given as IV infusion, Q4W for up to 13 doses.
ONC-392 highDrug
ONC-392 will be given as IV infusion, Q6W for up to 9 doses.
lutetium Lu 177 vipivotide tetraxetanDrug
lutetium Lu 177 vipivotide tetraxetan will be given as IV infusion, Q6W, for up to 6 doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLT (Dose escalation Phase 1)Time frame: 40 months
- PSA50 (Dose Expansion Phase 2)Time frame: 40 months
- rPFS (Dose Expansion Phase 2)Time frame: 40 months
- TEAEs and irAEs (Dose Expansion Phase 2)Time frame: 40 months
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
UC Davis Comprehensive Cancer Center
Sacramento, California
Rocky Mountain Cancer Centers USOR
Aurora, Colorado
Moffitt Cancer Cancer
Tampa, Florida
Emory University Winship Cancer Institute
Atlanta, Georgia
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Chesapeake Urology Research Associates
Towson, Maryland
Lahey Hospital & Medical Center
Burlington, Massachusetts
University of Mississippi Medical Center
Jackson, Mississippi
XCancer/GU Research Network
Omaha, Nebraska
Rutgers Cancer Institute
New Brunswick, New Jersey
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico
Roswell Park Comprehensive Cancer Center
Buffalo, New York
NYU Langone Health, Laura & Isaac Perlmutter Cancer Center
New York, New York
Columbia University Irving Cancer Center
New York, New York
UNC North Carolina Comprehensive Cancer Care Center
Chapel Hill, North Carolina
Duke Cancer Center
Durham, North Carolina
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
OHSU Knight Cancer Institute
Portland, Oregon
UT Southwestern Medical Center
Dallas, Texas
Virginia Cancer Specialists USOR
Fairfax, Virginia
Virginia Oncology Associates USOR
Norfolk, Virginia
Oncology and Hematology Associates Of Southwest Virginia USOR
Norton, Virginia
UW Carbone Cancer Center
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.